Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Sirnaomics Ltd. ( (HK:2257) ) has issued an announcement.
Sirnaomics Ltd. has announced a supplemental update on the allocation of net proceeds from its recent share subscription, amounting to approximately HK$206.0 million. The funds will primarily be used to advance the development and commercialization of its key drug candidates, including STP705 and STP122G, with a strategic focus on completing clinical trials by the end of 2027. This financial move is expected to bolster the company’s position in the biotech industry and support its ongoing efforts to enrich its product pipeline, ultimately benefiting shareholders.
The most recent analyst rating on (HK:2257) stock is a Hold with a HK$8.50 price target. To see the full list of analyst forecasts on Sirnaomics Ltd. stock, see the HK:2257 Stock Forecast page.
More about Sirnaomics Ltd.
Sirnaomics Ltd. is a pioneering company in the biotechnology industry, focusing on the development of transformative RNA-based therapeutics to address critical unmet medical needs across global markets.
Average Trading Volume: 1,167,439
Technical Sentiment Signal: Buy
Current Market Cap: HK$1.99B
For detailed information about 2257 stock, go to TipRanks’ Stock Analysis page.